gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
gptkbp:atccode
|
R03 BA02
|
gptkbp:available_on
|
generic drug
|
gptkbp:brand
|
gptkb:Entocort
gptkb:Pulmicort
gptkb:Rhinocort
|
gptkbp:casnumber
|
51333-22-3
|
gptkbp:category
|
Category B
|
gptkbp:chemical_formula
|
C25 H34 O6
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:clinical_use
|
maintenance therapy
acute exacerbations
long-term control
prevention of symptoms
|
gptkbp:contraindication
|
systemic fungal infections
hypersensitivity to budesonide
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
gptkbp:discovered_by
|
gptkb:1980s
|
gptkbp:excretion
|
urine
feces
|
gptkbp:formulation
|
gptkb:Spider-Man
gptkb:Skin
gptkb:tablet
gptkb:capsule
suspension
|
https://www.w3.org/2000/01/rdf-schema#label
|
budesonide
|
gptkbp:interacts_with
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
gptkbp:lifespan
|
2 to 3 hours
|
gptkbp:mechanism_of_action
|
glucocorticoid receptor agonist
|
gptkbp:metabolism
|
liver
|
gptkbp:route_of_administration
|
gptkb:Skin
oral
inhalation
|
gptkbp:side_effect
|
headache
nausea
cough
throat irritation
|
gptkbp:storage
|
room temperature
dry place
protected from light
|
gptkbp:used_for
|
gptkb:disease
gptkb:asthma
allergic rhinitis
|
gptkbp:bfsParent
|
gptkb:Breztri_Aerosphere
gptkb:Trixeo_Aerosphere
gptkb:Symbicort
|
gptkbp:bfsLayer
|
5
|